Assessment of the Prognostic and Treatment-Predictive Performance of the Combined HOXB13:IL17BR-MGI Gene Expression Signature in the Trans-ATAC Cohort.

摘要

We compared the prognostic ability of the Breast Cancer Index (BCI), Oncotype DX Recurrence Score (RS) and IHC4 for both early and late recurrence among patients with ER+, node negative (N0) disease with the ATAC clinical trial. BCI was performed from 1102 primary tumor samples from ER+ patients were evaluated. BCI-L, IHC4 and RS had significant prognostic performance for early DR (BCO-L, p<0-0002), while only BCI-L was significant for late DR (LR-(Delta)X2: 7-97, p=0-0048). For risk of early DR at 5 years, BCI-L classified 59%, 25%, and 16% of patients with 1.3%, 5.6% and 18.1% for low, intermediate and high risk, respectively. For risk of late DR at 10 years, BCI-L classified 61%, 25%, and 14% of patients.